These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39378565)

  • 1. Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
    Reck M; Granados ALO; de Marinis F; Meyers O; Shen Q; Cho L; Stjepanovic N; Boklage S
    Eur J Cancer; 2024 Nov; 212():115050. PubMed ID: 39378565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
    Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
    Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
    Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
    Mazieres J; Kowalski D; Luft A; Vicente D; Tafreshi A; Gümüş M; Laktionov K; Hermes B; Cicin I; Rodríguez-Cid J; Wilson J; Kato T; Ramlau R; Novello S; Reddy S; Kopp HG; Piperdi B; Li X; Burke T; Paz-Ares L
    J Clin Oncol; 2020 Jan; 38(3):271-280. PubMed ID: 31751163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
    Makharadze T; Quek RGW; Melkadze T; Gogishvili M; Ivanescu C; Giorgadze D; Dvorkin M; Penkov K; Laktionov K; Nemsadze G; Nechaeva M; Rozhkova I; Kalinka E; Gessner C; Moreno-Jaime B; Passalacqua R; Konidaris G; Rietschel P; Gullo G
    Cancer; 2023 Jul; 129(14):2256-2265. PubMed ID: 37151113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.
    Barlesi F; Garon EB; Kim DW; Felip E; Han JY; Kim JH; Ahn MJ; Fidler MJ; Gubens MA; de Castro G; Surmont V; Li Q; Deitz AC; Lubiniecki GM; Herbst RS
    J Thorac Oncol; 2019 May; 14(5):793-801. PubMed ID: 30711649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial.
    Lim SM; Peters S; Ortega Granados AL; Pinto GDJ; Fuentes CS; Lo Russo G; Schenker M; Ahn JS; Reck M; Szijgyarto Z; Huseinovic N; Zografos E; Buss E; Stjepanovic N; O'Donnell S; de Marinis F
    Nat Commun; 2023 Nov; 14(1):7301. PubMed ID: 37951954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
    Garon EB; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; Robinet G; Le Moulec S; Natale R; Schneider J; Shepherd FA; Garassino MC; Geater SL; Szekely ZP; Van Ngoc T; Liu F; Scheuring U; Patel N; Peters S; Rizvi NA
    Clin Lung Cancer; 2021 Jul; 22(4):301-312.e8. PubMed ID: 33775558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
    Oliveira M; Rugo HS; Howell SJ; Dalenc F; Cortes J; Gomez HL; Hu X; Toi M; Jhaveri K; Krivorotko P; Loibl S; Morales Murillo S; Okera M; Nowecki Z; Park YH; Sohn JH; Tokunaga E; Yousef S; Zhukova L; Fulford M; Andrews H; Wadsworth I; D'Cruz C; Turner NC;
    Lancet Oncol; 2024 Sep; 25(9):1231-1244. PubMed ID: 39214106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
    Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
    Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
    Garon EB; Cho BC; Luft A; Alatorre-Alexander J; Geater SL; Kim SW; Ursol G; Hussein M; Lim FL; Yang CT; Araujo LH; Saito H; Reinmuth N; Medic N; Mann H; Shi X; Peters S; Mok T; Johnson M
    Lung Cancer; 2023 Dec; 186():107422. PubMed ID: 37992595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.
    Pérol M; Pavlakis N; Levchenko E; Platania M; Oliveira J; Novello S; Chiari R; Moran T; Mitry E; Nüesch E; Liu T; Balas B; Konopa K; Peters S
    Lung Cancer; 2019 Dec; 138():79-87. PubMed ID: 31654838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
    Rischin D; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Braña I; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Ishak WZW; Hong RL; Mendoza RG; Jia L; Chirovsky D; Norquist J; Jin F; Burtness B
    Oral Oncol; 2022 May; 128():105815. PubMed ID: 35381576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishing Meaningful Change Thresholds in Patient-Reported Outcomes Among Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in ALTA-1L Trial.
    Beaumont JL; Lin HM; Goodman E; Yu H; Geiger A; Hudgens S
    Value Health; 2024 Feb; 27(2):182-189. PubMed ID: 37951539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.
    Leighl NB; Karaseva N; Nakagawa K; Cho BC; Gray JE; Hovey T; Walding A; Rydén A; Novello S
    Eur J Cancer; 2020 Jan; 125():49-57. PubMed ID: 31838405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Monk BJ; Tewari KS; Dubot C; Caceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüş M; Hurtado de Mendoza MO; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Martin Nguyen A; Monberg MJ; Colombo N; Lorusso D
    Lancet Oncol; 2023 Apr; 24(4):392-402. PubMed ID: 36878237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
    Goldman JW; Garassino MC; Chen Y; Özgüroğlu M; Dvorkin M; Trukhin D; Statsenko G; Hotta K; Ji JH; Hochmair MJ; Voitko O; Havel L; Poltoratskiy A; Losonczy G; Reinmuth N; Patel N; Laud PJ; Shire N; Jiang H; Paz-Ares L
    Lung Cancer; 2020 Nov; 149():46-52. PubMed ID: 32961445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
    Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ
    Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE).
    Necchi A; Nishiyama H; Matsubara N; Lee JL; Petrylak DP; de Wit R; Drakaki A; Liepa AM; Mao H; Bell-McGuinn K; Powles T
    BMC Urol; 2020 Nov; 20(1):181. PubMed ID: 33160359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.